• Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability
• Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract
• Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through various animal and human clinical studies

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is using its patented DehydraTECH(TM) technology to improve bioavailability and how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with the speed of onset, and brain absorption. Lexaria is focusing ongoing research and development efforts on the advancement of product candidates across several key segments, including, nicotine replacement, CBD, cardiovascular drugs, antivirals, epilepsy, human hormones, and PDE5 inhibitors.

Bioavailability measures how much of a substance enters the bloodstream, with intravenous administration being the most effective approach to 100% bioavailability for maximum effect. While oral administration is less intrusive and preferred, it presents less efficacy and bioavailability of APIs due to obstacles like gut disorders and stomach acid and liver biotransformation.

Although Lexaria is focused on pharmaceutical bioavailability, it’s interesting to note that bioavailability even plays a role in nutrition. While macronutrients (carbs and fat) offer higher levels of bioavailability – micronutrients, commonly sold as supplements (vitamins, minerals, flavonoids, and carotenoids), can be harder for the body to absorb. Studies show that not all the nutrients we eat enter the bloodstream after entering the digestive tract. Some factors that affect bioavailability include where the food is grown or made, when it was harvested, how it was prepared, the foods you eat with it, and highly individualized physiological traits that affect how your body processes that food.

With studies showing that around 40% of available drugs are poorly bioavailable (https://cnw.fm/wVOTV), the determined factors that affect drug bioavailability include:

• The size of the drug’s molecule
• The type of drug administered
• The amount of food eaten
• The time of day the drug is taken

Understanding the bioavailability of a drug is crucial for clinicians looking for appropriate routes of administration and schedule for drug delivery. Lexaria is investigating its DehydraTECH technology for increased bioavailability of APIs with epilepsy, high blood pressure, dementia, diabetes, and more.

The global pharmaceutical drug delivery market is projected to reach $2.21 billion by 2026, growing with a CAGR of 5.9% from a value of $1.66 billion in 2021. Growth is highly attributed to factors including the rising prevalence of chronic diseases, the growing biologics market, increased R&D investments, and technological advancements, which include new product launches (https://cnw.fm/KCUfM).

Animal studies have also demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery. Since 2016, Lexaria’s technology has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reduce the onset time from one to two hours to just minutes, and mask unwanted tastes.

The company’s recent study, EPIL-A21-1, demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). The study’s results have demonstrated the performance of DehydraTECH-CBD to reduce or eliminate seizure activity in animals and, in some cases, even surpass the performance of Epidiolex. The findings from the study further support Lexaria’s efforts and clinical trials, which are currently being explored for other indications, including hypertension, dementia, and diabetes. The indications explored by Lexaria are chosen due to their current underserved medical needs, as DehydraTECH helps enhance bioavailability of substances for treatment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.